ERBB2 Altered Breast Cancer
1 clinical trials · Condition
◉ Watch ERBB2 Altered Breast Cancer
| Record | Firm | Date |
|---|---|---|
| A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors (NCT07361562) | Cogent Biosciences, Inc. | 2025-12-30 |
Track ERBB2 Altered Breast Cancer automatically
Every clearance here is in the API, with alerts when new ones post.